Baird Is a Buyer of BioMarin (BMRN) On Genzyme-Related Weakness
BMRN Hot Sheet
Rating Summary:7 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 25 | Down: 12 | New: 36
Baird said they are buyers of BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) on weakness tied to Genzyme Corp. (Nasdaq: GENZ) Allston manufacturing suspension.
The firm notes, "Aldurazyme fill/finish was previously performed at this facility, but BMRN indicates Allston is now a secondary source and an outside, primary source has been validated for some time. Coupling this with BMRN's indication that at least a year's worth of Aldurazyme finished goods inventory is on hand, we see no impact to BMRN's revenue prospects."
The firm notes, "Aldurazyme fill/finish was previously performed at this facility, but BMRN indicates Allston is now a secondary source and an outside, primary source has been validated for some time. Coupling this with BMRN's indication that at least a year's worth of Aldurazyme finished goods inventory is on hand, we see no impact to BMRN's revenue prospects."
You May Also Be Interested In
- Barclays Maintains an 'Equalweight' on Trina Solar (TSL); Waiting on Growth in Gross Margins and Stabilized Opex
- Auriga Cuts PT and Estimates on HEICO (HEI); Cautious on Decelerating FSG Growth
- BMO Capital on NetApp (NTAP): Could Attract Interested Parties At These Levels; Prefers EMC
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
